← The Wire
XNCRNasdaq
Xencor Inc
Pharmaceutical Preparations · DE · CIK 1326732
Xencor discovers and develops engineered antibody therapeutics for cancer and autoimmune diseases using protein engineering
red 8-K · 90d
$914M
Market cap
$15.60
Last close
+3.6%
1D
+11.3%
5D
750K
Volume
Price · last 39 sessions+16.8%
May 4L $10.41 · H $15.60Jun 29
251
Total filings
Jun 18, 2026
Last filing
12/31
Fiscal year end
8-KShareholder VoteJun 18, 202610-Q10-QMay 6, 20268-KResults of OperationsMay 6, 20268-KReg FD DisclosureMay 5, 2026DEFA14ADEFA14AApr 27, 2026DEF 14ADEF 14AApr 27, 20268-KExecutive ChangeApr 27, 20268-KAgreement TerminatedMar 9, 20268-KReg FD DisclosureMar 4, 202610-K10-KFeb 25, 20268-KResults of OperationsFeb 25, 20268-KResults of OperationsJan 8, 202610-Q10-QNov 5, 20258-KResults of OperationsNov 5, 20258-KReg FD DisclosureOct 24, 202510-Q10-QAug 6, 20258-KResults of OperationsAug 6, 20258-KExecutive ChangeJul 31, 20258-KShareholder VoteJun 13, 202510-Q10-QMay 7, 20258-KExecutive Change · Results of OperationsMay 7, 20258-KReg FD DisclosureApr 30, 2025DEFA14ADEFA14AApr 23, 2025DEF 14ADEF 14AApr 23, 20258-K/AAuditor ChangeMar 13, 20258-KExecutive ChangeMar 13, 20258-KAuditor ChangeMar 5, 202510-K10-KFeb 27, 20258-KResults of OperationsFeb 27, 202510-Q/A10-Q/AFeb 24, 202510-Q/A10-Q/AFeb 24, 202510-Q/A10-Q/AFeb 24, 202510-K/A10-K/AFeb 24, 20258-KRestatementFeb 13, 20258-KResults of Operations · Reg FD DisclosureJan 13, 202510-Q10-QNov 6, 20248-KResults of OperationsNov 6, 2024SC 13GSC 13GOct 21, 20248-KExecutive ChangeOct 4, 20248-KCompany UpdateSep 12, 20248-KMaterial Agreement · Company UpdateSep 12, 2024424B5PROSPECTUS SUPPLEMENTSep 12, 2024424B5PROSPECTUS SUPPLEMENTSep 10, 20248-KReg FD Disclosure · Company UpdateSep 9, 202410-Q10-QAug 5, 20248-KResults of OperationsAug 5, 20248-KShareholder VoteJun 14, 20248-KCompany UpdateJun 13, 20248-KResults of OperationsMay 9, 202410-Q10-QMay 9, 2024DEFA14ADEFA14AApr 24, 2024DEF 14ADEF 14AApr 24, 20248-KExecutive ChangeApr 9, 20248-KReg FD DisclosureMar 6, 202410-K10-KFeb 29, 20248-KResults of OperationsFeb 27, 2024SC 13GSC 13GFeb 14, 20248-KMaterial AgreementNov 15, 202310-Q10-QNov 8, 20238-KResults of OperationsNov 7, 20238-KMaterial AgreementNov 7, 20238-KExecutive ChangeOct 26, 20238-KExecutive ChangeSep 19, 202310-Q10-QAug 3, 20238-KResults of OperationsAug 3, 20238-KExecutive ChangeJul 3, 20238-KShareholder VoteJun 15, 202310-Q10-QMay 8, 20238-KResults of OperationsMay 8, 2023DEFA14ADEFA14AApr 26, 2023DEF 14ADEF 14AApr 26, 20238-KExecutive ChangeApr 26, 20238-KReg FD DisclosureMar 13, 20238-KMaterial AgreementFeb 28, 202310-K10-KFeb 27, 20238-KResults of OperationsFeb 23, 2023SC 13GSC 13GFeb 15, 2023SC 13GSC 13GFeb 14, 2023SC 13GSC 13GFeb 6, 202310-Q10-QNov 7, 2022
Insider Activity
In the 90 days to Mar 6, 2026: 4 sold $3.5M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 6, 2026 | Dahiyat Bassil IPRESIDENT & CEO | Sell | 6,606 | $11.02 | $73K |
| Mar 6, 2026 | Desjarlais John RSR. VICE PRESIDENT & CSO | Sell | 2,502 | $11.02 | $28K |
| Mar 6, 2026 | Eckert CeliaSVP, GENERAL COUNSEL | Sell | 1,767 | $11.02 | $19K |
| Mar 5, 2026 | Dahiyat Bassil IPRESIDENT & CEO | Sell | 14,870 | $11.25 | $167K |
| Mar 5, 2026 | Desjarlais John RSR. VICE PRESIDENT & CSO | Sell | 4,118 | $11.25 | $46K |
| Mar 5, 2026 | Eckert CeliaSVP, GENERAL COUNSEL | Sell | 3,244 | $11.25 | $36K |
| Mar 5, 2026 | Cornelissen Bart JanSR. VICE PRESIDENT & CFO | Sell | 2,517 | $11.25 | $28K |
| Mar 3, 2026 | Dahiyat Bassil IPRESIDENT & CEO | Sell | 6,758 | $11.90 | $80K |
| Mar 3, 2026 | Desjarlais John RSR. VICE PRESIDENT & CSO | Sell | 2,663 | $11.90 | $32K |
| Mar 3, 2026 | Eckert CeliaSVP, GENERAL COUNSEL | Sell | 1,492 | $11.90 | $18K |
| Dec 19, 2025 | Dahiyat Bassil IPRESIDENT & CEO | Sell | 114,377 | $15.71 | $1.8M |
| Dec 19, 2025 | Desjarlais John RSR. VICE PRESIDENT & CSO | Sell | 73,367 | $15.72 | $1.2M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance